Summary
The purpose of this study is to assess if adding LY3537982 in combination with standard of care anti-cancer drugs is more effective than standard of care in participants with untreated advanced NSCLC. NSCLC must have a change in a gene called KRAS G12C. Study participation, including follow-up, could last up to 3 years, depending on how you and your lung cancer are doing.
Official Title
SUNRAY-01, A Global Pivotal Study in Participants With KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in Those With PD-L1 Expression ≥50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum Regardless of PD-L1 Expression
Details
Dose Optimization, Part A, and Part B are randomized. Safety Lead-In for Part B is single arm, non-randomized.
Keywords
Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Non-Small-Cell Lung Carcinoma, Carboplatin, Pembrolizumab, Pemetrexed, Cisplatin, Safety Lead In: LY3537982 plus Pembrolizumab, Pemetrexed and Platinum, LY3537982 plus Pembrolizumab, LY3537982 plus Pembrolizumab, Pemetrexed, and Platinum